Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age : an exploratory analysis from the RE-SONANCE study

Simple item page
dc.contributor.authorVinereanu, Dragos
dc.contributor.authorNapalkov, Dmitry
dc.contributor.authorBergler-Klein, Jutta
dc.contributor.authorBenczur, Bela
dc.contributor.authorCiernik, Martin
dc.contributor.authorGotcheva, Nina
dc.contributor.authorMedvedchikov, Alexey
dc.contributor.authorPõder, Pentti
dc.contributor.authorSimić, Dragan
dc.contributor.authorSkride, Andris
dc.contributor.authorTang, Wenbo
dc.contributor.authorTrusz-Gluza, Maria
dc.contributor.authorVesely, Jiří
dc.contributor.institutionRīga Stradiņš University
dc.date.accessioned2022-01-28T10:50:01Z
dc.date.available2022-01-28T10:50:01Z
dc.date.issued2021-11
dc.descriptionFunding Information: The authors thank all the patients who participated in this study. Medical writing support was provided by Parexel, with funding from Boehringer Ingelheim GmbH. Funding Information: Dragos Vinereanu received grants and personal fees from Boehringer Ingelheim during the conduct of the study; grants and personal fees from Bristol-Myers Squibb, Pfizer, Bayer, Johnson & Johnson, and Daiichi Sankyo outside the submitted work. Dmitry Napalkov received research grants and has participated in scientific advisory boards for Boehringer Ingelheim and has received speaker’s honoraria from Bayer, Boehringer Ingelheim, Pfizer, and Takeda. Bela Benczur received speaker’s/consultancy fees from Bayer, Berlin-Chemie/Menarini, Boehringer Ingelheim, Krka Pharma, Novartis, Pfizer, Sandoz, and Sanofi. Martin Ciernik, Alexey Medvedchikov, and Wenbo Tang are employees of Boehringer Ingelheim. Pentti Põder received educational grants from Boehringer Ingelheim. Maria Trusz-Gluza received personal fees from Boehringer Ingelheim (null during the conduct of the study), personal fees and non-financial support from Boehringer Ingelheim, and personal fees from Bayer outside the submitted work. Jiří Vesely received personal fees and non-financial support from Bayer, Boehringer Ingelheim, Pfizer, MSD, and PRO.MED.CS outside the submitted work. All other authors report no conflicts of interest. Publisher Copyright: © 2021, The Author(s).
dc.description.abstractBackground: The oral anticoagulant dabigatran offers an effective alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), yet patient preference data are limited. The prospective observational RE-SONANCE study demonstrated that patients with AF, newly initiated on dabigatran, or switching to dabigatran from long-term VKA therapy, reported improved treatment convenience and satisfaction compared with VKA therapy. This pre-specified sub-study aimed to assess the impact of country and age on patients’ perceptions of dabigatran or VKA therapy in AF. Methods: RE-SONANCE was an observational, prospective, multi-national study (NCT02684981) that assessed treatment satisfaction and convenience in patients switching from VKAs to dabigatran (Cohort A), or newly diagnosed with AF receiving dabigatran or VKAs (Cohort B), using the PACT-Q questionnaire. Pre-specified exploratory outcomes: variation in PACT-Q2 scores by country and age (< 65, 65 to < 75, ≥ 75 years) (both cohorts); variation in PACT-Q1 responses at baseline by country and age (Cohort B). Results: Patients from 12 countries (Europe/Israel) were enrolled in Cohort A (n = 4103) or B (n = 5369). In Cohort A, mean (standard deviation) PACT-Q2 score increase was highest in Romania (convenience: 29.6 [23.6]) and Hungary (satisfaction: 26.0 [21.4]) (p < 0.001). In Cohort B, mean (standard error) increase in PACT-Q2 scores between dabigatran and VKAs was highest in Romania (visit 3: 29.0 [1.3]; 24.5 [0.9], p < 0.001). Mean PACT-Q2 score increase by age (all p < 0.001) was similar across ages. PACT-Q1 responses revealed lowest expectations of treatment success in Romania and greatest concerns about payment in Estonia, Latvia, and Romania, but were similar across ages. Conclusions: Treatment satisfaction and convenience tended to favor dabigatran over VKAs. Regional differences in treatment expectations exist across Europe. Trial and clinical registry: Trial registration number: ClinicalTrials.gov NCT02684981. Trial registration date: February 18, 2016.en
dc.description.statusPeer reviewed
dc.format.extent12
dc.format.extent1179923
dc.identifier.citationVinereanu, D, Napalkov, D, Bergler-Klein, J, Benczur, B, Ciernik, M, Gotcheva, N, Medvedchikov, A, Põder, P, Simić, D, Skride, A, Tang, W, Trusz-Gluza, M & Vesely, J 2021, 'Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age : an exploratory analysis from the RE-SONANCE study', Journal of Thrombosis and Thrombolysis, vol. 52, no. 4, pp. 1195-1206. https://doi.org/10.1007/s11239-021-02450-2
dc.identifier.doi10.1007/s11239-021-02450-2
dc.identifier.issn0929-5305
dc.identifier.otherMendeley: 55a09b00-545f-3e86-aefe-3a58f90e7126
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/7362
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85105393328&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofJournal of Thrombosis and Thrombolysis
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAtrial fibrillation
dc.subjectDabigatran
dc.subjectNon‐vitamin K antagonist oral anticoagulant
dc.subjectPatient perception
dc.subjectStroke prevention
dc.subjectWarfarin
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectHematology
dc.subjectCardiology and Cardiovascular Medicine
dc.titlePatient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age : an exploratory analysis from the RE-SONANCE studyen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Patient_perceptions_of_anticoagulant_treatment.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure